Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.41 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PDCD4 | Q53EL6 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30787426 | 0.98 | GPR84 (0.52) | GPR84FFAR1FFAR4NFKB1SPHK1 | |
| SCHEMBL30787195 | 0.98 | GPR84 (0.52) | GPR84FFAR1FFAR4NFKB1SPHK1 | |
| SCHEMBL29184948 | 0.98 | GPR84 (0.52) | GPR84FFAR1FFAR4NFKB1SPHK1 | |
| SCHEMBL30787245 | 0.98 | GPR84 (0.52) | GPR84FFAR1FFAR4NFKB1SPHK1 | |
| SCHEMBL28395902 | 0.98 | GPR84 (0.52) | GPR84FFAR1FFAR4NFKB1SPHK1 | |
| SCHEMBL30787286 | 0.98 | GPR84 (0.52) | GPR84FFAR1FFAR4NFKB1SPHK1 | |
| SCHEMBL30787360 | 0.98 | GPR84 (0.52) | GPR84FFAR1FFAR4NFKB1SPHK1 | |
| SCHEMBL6925758 | 0.98 | GPR84 (0.52) | GPR84FFAR1FFAR4NFKB1SPHK1 | |
| SCHEMBL30787160 | 0.98 | GPR84 (0.52) | GPR84FFAR1FFAR4NFKB1SPHK1 | |
| SCHEMBL22249537 | 0.95 | GPR84 (0.50) | GPR84FFAR1FFAR4NFKB1SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6899753-B2 | Highly bleed-alleviating ink composition | BENQ CORPORATION (TW) | 2005-05-31 | — | — | US | claimed |
| US-20030037700-A1 | Highly bleed-alleviating ink composition | MIND FUSION, LLC | 2003-02-27 | — | — | US | claimed |
| CN-116135866-A | Bridged carboxylic acid-containing difunctional phosphine ligand, preparation method and application thereof | 中山大学 | 2023-05-19 | — | — | CN | disclosed |
| EP-2700636-B1 | PROCESS FOR PREPARING EPISULFIDE COMPOUNDS | ASAHI CHEMICAL IND (JP) | 2017-08-02 | — | — | EP | disclosed |
| US-9359324-B2 | Process for preparing episulfide compounds | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2016-06-07 | — | — | US | disclosed |
| CN-103476764-B | Process for producing episulfide compound | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2016-05-25 | — | — | CN | disclosed |
| EP-2928938-A1 | RADIATION-CURABLE AQUEOUS POLYURETHANE DISPERSIONS | BASF SE (DE) | 2015-10-14 | — | — | EP | disclosed |
| US-20150197501-A1 | Process for Preparing Episulfide Compounds | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2015-07-16 | — | — | US | disclosed |
| US-9051293-B2 | Process for preparing episulfide compounds | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2015-06-09 | — | — | US | disclosed |
| CN-104610222-A | Process for preparing episulfide compounds | ASAHI KASEI CHEMICALS CORP | 2015-05-13 | — | — | CN | disclosed |
| EP-2855553-A1 | RADIATION-CURABLE COMPOUNDS | BASF SE (DE) | 2015-04-08 | — | — | EP | disclosed |
| EP-1902082-A1 | COATING MASSES COMPRISING 2,4'-DIISOCYANATODIPHENYLMETHANE | BASF SE (DE) | 2008-03-26 | — | — | EP | disclosed |
| EP-1856173-A1 | RADIATION-CURABLE AQUEOUS POLYURETHANE DISPERSIONS | BASF AKTIENGESELLSCHAFT (DE) | 2007-11-21 | — | — | EP | disclosed |
| WO-2007063025-A1 | RADIATION-CURABLE DISPERSIBLE POLYURETHANES AND POLYURETHANE DISPERSIONS | BASF SE (DE) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007000415-A1 | COATING MASSES COMPRISING 2,4'-DIISOCYANATODIPHENYLMETHANE | BASF AKTIENGESELLSCHAFT (DE) | 2007-01-04 | — | — | WO | disclosed |
| WO-2006089935-A1 | RADIATION-CURABLE AQUEOUS POLYURETHANE DISPERSIONS | BASF AKTIENGESELLSCHAFT (DE) | 2006-08-31 | — | — | WO | disclosed |
| US-6899753-B2 | Highly bleed-alleviating ink composition | BENQ CORPORATION (TW) | 2005-05-31 | — | — | US | disclosed |
| CN-1401710-A | Ink composition with high ink bleeding prevention | BENQ CORP (CN) | 2003-03-12 | — | — | CN | disclosed |
| US-20030037700-A1 | Highly bleed-alleviating ink composition | MIND FUSION, LLC | 2003-02-27 | — | — | US | disclosed |
| WO-1998017750-A1 | CONCENTRATED, FABRIC SOFTENING COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197501-A1 | Process for Preparing Episulfide Compounds | TST, EPHX2, STS | GPR84 3934/4885FFAR1 4701/4885FFAR4 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.